Pembrolizumab in Refractory Advanced Esophageal Cancer

Clinical trial NCT02971956 · COMPLETED

Trial details

NCT number: NCT02971956
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Cancer Squamous Cell Esophagus Cancer Adenocarcinoma Esophagus

Start date: 2017-01-18
Primary completion: 2019-07-23
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.